Metraipolis › archive › dc_962fb4043051

A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3-Expressing Relapsed or Refractory Solid Tumors — Europe PMC PMID:40794737

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40794737
DOI
10.1158/2767-9764.crc-25-0293
License (as archived)
solo-consultazione
Archived
2026-10-07T16:32:31.594Z
SHA-256 of the archived text
4262670cf9928431aab72103ee9af65f76766801659514b00e4e7b9d164b6aed
Stable URL of this page
https://metraipolis.com/documento/dc_962fb4043051

How to cite

A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3-Expressing Relapsed or Refractory Solid Tumors — Europe PMC PMID:40794737 — Europe PMC (en), https://europepmc.org/article/MED/40794737 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_962fb4043051 (Metraipolis archive dc_962fb4043051, sha256 4262670cf9928431aab72103ee9af65f76766801659514b00e4e7b9d164b6aed)
BibTeX
@misc{dc962fb4043051,
  title = {A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3-Expressing Relapsed or Refractory Solid Tumors — Europe PMC PMID:40794737},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40794737},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_962fb4043051; sha256 4262670cf9928431aab72103ee9af65f76766801659514b00e4e7b9d164b6aed},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40794737. Agents can read the archived copy with the MCP tool read_document.